Introduction
Liver cirrhosis (LC) is a common chronic progressive liver disease with diffuse liver damage, which usually results from prolonged or repeated alcohol excess, viral hepatitis and other etiologies.
1,2 LC is characterized as reduced liver regeneration and hepatic dysfunction, which can lead to portal hypertension with serious complications including ascites, hepatic encephalopathy, secondary infection and so on. 3, 4 Incidence of LC and mortality caused by LC had risen remarkably in the past few decades, and the patients were usually diagnosed at the irreversible state. 1 Although survival has been improved due to effective LC management, it still ranks high among the world's leading causes of death. 2, 5 Liver transplantation is the only curative treatment for patients with decompensated LC, 5 but it confronts with problems such as donor shortage, submit your manuscript | www.dovepress.com
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Tao et al high medical costs, surgical complications, immunological rejection and ethical restraints. 3, 5 Liver transplantation failure may cause extensive and progressive fibrosis, which restrains liver regeneration and causes irreversible cirrhosis. 3 Researchers have been exploring new approaches to promote liver regeneration, 3 and stem cell therapy was considered as a promising treatment strategy. 6, 7 Preclinical LC studies on stem cell transplantation have shown beneficial effects, and the most commonly used cells were mesenchymal stem cells (MSCs), [8] [9] [10] hepatic progenitor cells (HPCs) 11, 12 and hematopoietic stem cells (HSCs), 13, 14 which were usually obtained from autologous or allogeneic bone marrow. 4, 12 However, the procedure of bone marrow aspiration was invasive, and quantity and quality of bone marrow stem cells (BMSCs) are age-dependent, which limit their clinical potentiality. [15] [16] [17] [18] As an alternative source of BMSCs, umbilical cord blood stem cells (USCs) showed promising clinical application prospects. USCs are composed of immature immune cells and multipotent stem cells such as MSCs, endothelial progenitor cells (EPCs) and HSCs. 16, 17 They can migrate to injury sites due to chemotaxis, differentiate into various types of cells such as osteoblasts, chondrocytes and hepatocytes cells and secrete various cytokines and growth factors. 19 Compared to BMSCs, USCs are more accessible with fewer ethical constraints. 17, 18, 20 Clinical trials reported that USCs transfusion could ameliorate liver fibrosis and improve liver functions without significant side effects. 21, 22 In comparison with LC patients treated by routine supportive therapy (RST), those who underwent RST and USCs combined therapy exhibited more prominent therapeutic effects. In this study, we conducted a meta-analysis to systematically evaluate the therapeutic efficacy and safety of USCs and RST combined therapy in comparison with RST alone for LC, in order to provide scientific basis for future research and clinical application.
Materials and methods search strategy and selection criteria
We performed literature search across Web of Science, PubMed, EMBASE, Cochrane Library, Wanfang and CNKI database with key terms "stem cells" OR "umbilical cord blood stem cells", AND "liver cirrhosis" OR "hepatocirrhosis", without language restriction. Literature studies published before April 2017 were involved in this analysis.
The selection criteria are listed as follows: case-controlled trials involving .30 LC patients; participants diagnosed with LC, without malignant tumor and not pregnant or lactating; patients in the experimental group who received USCs and RST combined therapy, and those in the control group who were treated by RST alone.
Data extraction and quality assessment
Two authors (Huimin Tao and Yafeng Li) collected and summarized data independently, including author's names, years of publication, locations, patients' ages and LC stages, samples sizes, causes of LC, therapeutic regimens, administration routes, number of USCs and study parameter types. Trials' quality was evaluated by following the instructions of Cochrane Handbook. 23 
Outcome definition
Clinical responses evaluated in this research included treatment efficacy, quality of life (QoL) and adverse events. Treatment efficacy was assessed in terms of levels of total bilirubin (TBIL), serum albumin (ALB), alanine aminotransferase (ALT), aspartate aminotransferase (AST), prothrombin time (PT), prothrombin activity (PTA) and Child-Pugh score. Patients' QoL covered the following indicators: fatigue, appetite, abdominal distension, ascitic fluid and edema.
statistical analysis
We performed analysis using Review Manager 5.2 (Cochrane Collaboration). P,0.05 indicates differences with statistical significance. Appropriate analysis model was determined by heterogeneity according to Cochran's Q test. 24 Studies with I 2 ,50% or P.0.1 was considered homogenous, and fixed-effects model was applied; otherwise a random-effects model was applied. 25 Therapeutic efficacy was evaluated by odds ratio (OR) and presented with 95% CI.
Publication bias was evaluated based on the funnel plot. Sensitivity analyses were also performed to assess the impact of number of infused cells (.1×10 8 or ,1×10
8
) and routes of cell administration (intravenous or hepatic artery infusion).
Results
search results
A total of 5,323 articles were initially identified, and 5,227 were excluded due to the lack of clinical trials (n=4,876), duplication and repetition (n=187) or were unrelated studies (n=164). After full-text assessment, 18 reviews or metaanalyses, 12 articles without control group, 48 studies without USCs transplantation and 8 with insufficient data were also excluded. After selection, 10 trials [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] with 616 LC patients were included in this meta-analysis ( Figure 1 ).
Characteristics of patients
All trials that met our selection criteria were conducted in People's Republic of China. In total, 327 LC patients accepted USCs and RST combined therapy, and 289 patients were treated by RST alone. 
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UsCs transplantation as an adjunctive treatment strategy for lC USCs were obtained from healthy full-term infant's umbilical cord blood and were infused to LC patients through hepatic artery (n=6), portal vein (n=1) or peripheral vein (n=3), respectively. Detailed information of the involved studies and participants is summarized in Tables 1 and 2 .
Quality assessment
Risk of bias assessment is shown in Figure 2 . Six studies had low risk and the other 4 studies did not have clear description of randomization process. All studies had low risk of bias on allocation, performance and detection. One trial missing follow-up study and 1 trial missing primary outcome data had high risk of bias, and 2 studies with selective reporting had unclear risk of bias.
Therapeutic efficacy assessments
Random-effects meta-analysis was used to analyze the OR rate of the following descriptive indicators because of their high heterogeneity.
effectiveness of UsCs on TBil, alB, alT, asT and coagulation function As shown in Figure 3A , the TBIL level was reduced after combined therapy. This reduction was statistically significant 
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UsCs transplantation as an adjunctive treatment strategy for lC The random-effects meta-analysis model (inverse variance method) was used. Abbreviations: iV, inverse variance method; TBil, total bilirubin; alB, albumin; alT, alanine aminotransferase; asT, aspartate aminotransferase; PT, prothrombin time; PTa, prothrombin activity.
-100 Figure S1A ). The ALB level was increased after combined therapy, especially in the 4th, 8th, 12th and 24th week ( Figure 3B, The ALB level in the combined therapy group was also higher than that of the control group in the 4th, 8th, 12th and 24th week after therapy ( Figure S1B ).
After combined therapy, the ALT level was significantly reduced in the 4th and 8th week ( Figure 3C, 
01).
No statistical differences were observed in the ALT level between the 2 groups ( Figure S1C ).
As shown in Figure 3D , the AST level was significantly reduced only in the 8th week after combined therapy 
74).
Comparison between the 2 groups indicated that the AST level significantly decreased in the 8th week in the combined therapy group ( Figure S1D) .
The blood coagulation was evaluated in terms of PT and PTA. After combined therapy, PT was reduced in the 4th, 8th, 12th and 24th week ( Figure 3E with patients treated by RST alone, shorter PT were observed in combined therapy-treated patients in the 8th, 12th and 24th week after treatment ( Figure S1E ).
As shown in Figure 3F , in the 8th week after combined therapy, PTA was statistically increased (2nd: OR=5. 20 22.14, P=0.20) . Meanwhile, the pooled results showed that in the 8th week after treatment, patients who underwent combined therapy had more significantly increased PTA compared with patients who received RST alone ( Figure S1F ).
All the abovementioned results indicated that the combination of USCs and RST had better therapeutic effects for LC patients than RST alone.
Qol assessment
QoL of patients who received combined therapy was significantly improved compared to those treated by RST alone, indicated by better appetite, relieved ascitic fluid and abdominal distension after USCs treatment ( Figure 4 , appetite: OR=5. 43 
adverse events assessment
We evaluated safety of USCs therapy in this meta-analysis. The most common side effect during treatment was fever, which usually subsided within 24 hours without treatment. No serious adverse events or death were reported after USCs therapy (Table 3) . However, all trials did not compare the incidence of side effects in experimental and control groups.
Publication bias
Funnel plots of TBIL, ALB, ALT and PT data were symmetrical in general, indicating small publication bias (Figures 5 and S2 ).
sensitivity analysis
Subgroup analyses were performed to evaluate the effects of cell numbers (.1×10 8 or ,1×10 
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Tao et al through hepatic artery was more effective in reducing the TBIL level and PT, but less valid in increasing the ALB level (Tables 4 and S1 ).
Discussion
Stem cells derived from umbilical cord blood are mainly composed of HSCs, MSCs, EPCs and immature immunological cells. 16 HSCs and MSCs can differentiate into functional hepatocyte-like cells both in vitro and in vivo. 36, 37 Their anti-inflammatory and paracrine function can affect liver function. 5 MSCs can migrate and home to injured liver tissue, 38 differentiate into hepatocytes, inhibit hepatocytes death, 39 stimulate endogenous hepatocyte regeneration and promote the secretion of HGF, epidermal growth factor 
Control Events
Li et al (2013) 26 Wang et al (2012) 29 Zhang et al (2015) 31 Zhou et al (2013) 32 Zhu and Han (2014) 35 
Total (95% Cl) Total events
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Li et al (2013) 26 Zhang et al (2015) 31 Zhou et al (2013) 32 Zhu and Han (2014) 35 Total (95% Cl) Total events
Li et al (2013) 26 Wang et al (2012) 29 Zhang et al (2015) 31 
Zhou et al (2013) 32
Total (95% Cl) Total events
Study or subgroup
Li et al (2013) 26 
Zhou et al (2013) 32
Total (95% Cl) Total events Li et al (2013) 26 Wang et al (2012) 29 Zhou et al (2013) 32 Zhu and Han (2014) 46 found that MSCs remarkably inhibited the proliferation of hepatic stellate cells through activation of Notch and PI3K/Akt signaling pathways. EPCs have potential to regenerate the vascular endothelium in liver. 5, 47 Therefore, USCs were considered with promising prospective to treat LC.
In recent years, several studies have shown that USCs were safe and feasible treatment for LC. However, the different clinical protocols among those studies may lead to different therapeutic effects. In this study, we investigated published clinical trials extensively to achieve high statistical reliability. Our meta-analysis revealed that compared to LC patients who received RST alone, those treated by USCs and RST combined therapy exhibited more favorable efficacy, 
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Tao et al including increased ALB and PTA levels, and decreased TBIL, ALT, AST levels and PT, although changes in TBIL and ALT levels did not show statistical significance. Patients' QoL was remarkably improved after USCs therapy, including improved appetite and relieved fatigue, abdominal distension, ascitic fluid and edema. These results indicated that the combination of USCs transplantation and RST had more satisfied therapeutic effects for LC patients than those treated by RST alone.
USCs have been clinically applied to treat hematological malignancies for more than 2 decades with a good safety record. In this research, our analyses showed that USCs were also safe to treat LC. Fever was the most common side effect during USCs therapy, which in most cases resolved naturally, and no serious adverse events or death occurred during therapy.
Some factors may influence the therapeutic effects of USCs therapy, such as USCs dosages and infusion routes. Number of infused USCs is one of the primary determinations in therapeutic strategy optimization. Nakamura et al found that human CD34 + cell transplantation after chronic liver injury aroused functional regeneration in a dose-dependent manner. 48 Our analysis also revealed that a larger number of infused USCs were associated with more satisfied efficacy.
Moreover, we found that USCs infusion through hepatic artery was more effective in reducing TBIL and PT but not in increasing ALB compared to intravenous perfusion. However, currently available publications probing the impact of administration routes on USCs' curative effect are still insufficient, and more data will be needed to perform convincible statistical analysis. We expect our study will be valuable for the design of upcoming comprehensive clinical trials.
Our study has some limitations. The numbers of LC patients included in this study was not big enough and the follow up periods was short. Although the effectiveness of USCs therapy on hematological, nerve and other system diseases have been reported, [49] [50] [51] [52] but its application on LC was still mainly performed in People's Republic of China. This may be because there are a large number of Chinese LC patients and many Chinese research studies were focused on it, therefore abundant papers were generated. Moreover, the therapeutic effects of USCs therapy are affected by multiple factors, such as injection modes, infused USCs numbers and LC stages. Further detailed analyses need to be conducted based on research studies with sufficient information, standardized therapeutic regimens and strict patients inclusion criteria. Although the therapeutic effects of USCs for LC were satisfied, which 
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UsCs transplantation as an adjunctive treatment strategy for lC population of cells among USCs was mainly responsible for these effects was unclear, and the underlying mechanism remained elusive. Qi et al 5 assumed that the improved liver microenvironments and/or the increased hepatocytes number may help liver function recovery after stem cell therapy.
Conclusion
This study confirmed the efficacy and safety of USCs transplantation and RST combined therapy for LC patients. USCs therapy greatly enhanced the improvement in liver function after RST and improved QoL of LC patients. Therefore, USCs transplantation and RST combined therapy is a promising treatment option for LC patients.
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